Survival in women with MMR mutations and ovarian cancer

A multicentre study in Lynch syndrome kindreds

Eli Marie Grindedal, Laura Renkonen-Sinisalo, Hans Vasen, Gareth Evans, Paola Sala, Ignacio Blanco, Jacek Gronwald, Jaran Apold, Diana M. Eccles, Ángel Alonso Sánchez, Julian Sampson, Heikki J. Järvinen, Lucio Bertario, Gillian C. Crawford, Astrid Tenden Stormorken, Lovise Maehle, Pal Moller

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12% lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5% had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6%, compared to less than 40% that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5%, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3%. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalJournal of Medical Genetics
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Ovarian Neoplasms
Multicenter Studies
Mutation
Survival
Germ-Line Mutation
Colonic Neoplasms
Population
Genes
Neoplasms
Retrospective Studies

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Grindedal, E. M., Renkonen-Sinisalo, L., Vasen, H., Evans, G., Sala, P., Blanco, I., ... Moller, P. (2010). Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 47(2), 99-102. https://doi.org/10.1136/jmg.2009.068130

Survival in women with MMR mutations and ovarian cancer : A multicentre study in Lynch syndrome kindreds. / Grindedal, Eli Marie; Renkonen-Sinisalo, Laura; Vasen, Hans; Evans, Gareth; Sala, Paola; Blanco, Ignacio; Gronwald, Jacek; Apold, Jaran; Eccles, Diana M.; Sánchez, Ángel Alonso; Sampson, Julian; Järvinen, Heikki J.; Bertario, Lucio; Crawford, Gillian C.; Stormorken, Astrid Tenden; Maehle, Lovise; Moller, Pal.

In: Journal of Medical Genetics, Vol. 47, No. 2, 02.2010, p. 99-102.

Research output: Contribution to journalArticle

Grindedal, EM, Renkonen-Sinisalo, L, Vasen, H, Evans, G, Sala, P, Blanco, I, Gronwald, J, Apold, J, Eccles, DM, Sánchez, ÁA, Sampson, J, Järvinen, HJ, Bertario, L, Crawford, GC, Stormorken, AT, Maehle, L & Moller, P 2010, 'Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds', Journal of Medical Genetics, vol. 47, no. 2, pp. 99-102. https://doi.org/10.1136/jmg.2009.068130
Grindedal, Eli Marie ; Renkonen-Sinisalo, Laura ; Vasen, Hans ; Evans, Gareth ; Sala, Paola ; Blanco, Ignacio ; Gronwald, Jacek ; Apold, Jaran ; Eccles, Diana M. ; Sánchez, Ángel Alonso ; Sampson, Julian ; Järvinen, Heikki J. ; Bertario, Lucio ; Crawford, Gillian C. ; Stormorken, Astrid Tenden ; Maehle, Lovise ; Moller, Pal. / Survival in women with MMR mutations and ovarian cancer : A multicentre study in Lynch syndrome kindreds. In: Journal of Medical Genetics. 2010 ; Vol. 47, No. 2. pp. 99-102.
@article{f532dc9830db422bbfdec44ac945b59a,
title = "Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds",
abstract = "Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12{\%} lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5{\%} had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6{\%}, compared to less than 40{\%} that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5{\%}, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3{\%}. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10{\%} and a risk of dying of ovarian cancer of 20{\%} gave a lifetime risk of dying of ovarian cancer of about 2{\%} in female MMR mutation carriers.",
author = "Grindedal, {Eli Marie} and Laura Renkonen-Sinisalo and Hans Vasen and Gareth Evans and Paola Sala and Ignacio Blanco and Jacek Gronwald and Jaran Apold and Eccles, {Diana M.} and S{\'a}nchez, {{\'A}ngel Alonso} and Julian Sampson and J{\"a}rvinen, {Heikki J.} and Lucio Bertario and Crawford, {Gillian C.} and Stormorken, {Astrid Tenden} and Lovise Maehle and Pal Moller",
year = "2010",
month = "2",
doi = "10.1136/jmg.2009.068130",
language = "English",
volume = "47",
pages = "99--102",
journal = "Journal of Medical Genetics",
issn = "0022-2593",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Survival in women with MMR mutations and ovarian cancer

T2 - A multicentre study in Lynch syndrome kindreds

AU - Grindedal, Eli Marie

AU - Renkonen-Sinisalo, Laura

AU - Vasen, Hans

AU - Evans, Gareth

AU - Sala, Paola

AU - Blanco, Ignacio

AU - Gronwald, Jacek

AU - Apold, Jaran

AU - Eccles, Diana M.

AU - Sánchez, Ángel Alonso

AU - Sampson, Julian

AU - Järvinen, Heikki J.

AU - Bertario, Lucio

AU - Crawford, Gillian C.

AU - Stormorken, Astrid Tenden

AU - Maehle, Lovise

AU - Moller, Pal

PY - 2010/2

Y1 - 2010/2

N2 - Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12% lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5% had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6%, compared to less than 40% that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5%, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3%. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.

AB - Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12% lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5% had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6%, compared to less than 40% that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5%, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3%. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.

UR - http://www.scopus.com/inward/record.url?scp=77349086189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77349086189&partnerID=8YFLogxK

U2 - 10.1136/jmg.2009.068130

DO - 10.1136/jmg.2009.068130

M3 - Article

VL - 47

SP - 99

EP - 102

JO - Journal of Medical Genetics

JF - Journal of Medical Genetics

SN - 0022-2593

IS - 2

ER -